RCS - Oxford Biomedica PLC - Hardman Research: Major deal to supply Novartis <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

07/07/2017 10:15

RNS Number : 4476K
Oxford Biomedica PLC
07 July 2017
Hardman Research: Major deal to supply Novartis
Major deal to supply Novartis CAR-T programmes -OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector platform. OXB has made two significant announcements during the past week which reduce risk and greatly improve sentiment towards the stock. First, refinancing of its existing loan with a new, more favourable debt facility from Oakland Capital. Secondly, a deal with Novartis to supply vector for use in the manufacture of certain CAR-T therapies.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/07.07.17-major-deal-to-supply-novartis-car-t-programmes.pdf
To contact us: 
Hardman & Co
35 New Broad Street
London
EC2M 1NH
Contacts:
Dr Martin Hall
mh@hardmanandco.com 
Dr Dorothea Hill
dmh@hardmanandco.com
Dr Gregoire Pave
gp@hardmanandco.com
Telephone: +44 20 7194 7622
Follow us on Twitter @HardmanandCo
www.hardmanandco.com 
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors,and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAMMGGNLNZGNZG